Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vi-CRM197 Booster Response in Adults
NCT01438996Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2011
- Primary completion
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Vi-CRM197 in typhoid fever (3 arms), sponsored by Novartis. Primary endpoints: Anti-Vi ELISA Geometric Mean Concentration at 28 days and Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titers at 28 days. Started Oct 2011; status: completed.
02
Drugs
Vi-CRM197
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT01438996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438996.